Insider Buying Signals: Mark Boulding’s 10b5‑1 Purchase Fuels Confidence in PTC Therapeutics

Insider Buying Signals Amid a Wave of Sales at PTC Therapeutics

On April 6, 2026, Mark Boulding, the Executive Vice President and Chief Legal Officer of PTC Therapeutics, executed a Rule 10b5‑1 plan purchase of 2,265 shares of the company’s common stock at a weighted‑average price of $39.42 per share. This transaction is noteworthy because it occurs against a backdrop of a flurry of prior sales by Mr. Boulding in the preceding months, most of which were conducted under the same 10b5‑1 schedule. Although the purchase price is roughly half the current market value (US $69.58), it demonstrates a willingness to commit capital to PTC even when its shares are trading well above the plan’s trigger price.

What the Activity Means for Investors

The combination of buying and selling is a classic “cycle” pattern often observed in high‑growth biotechnology firms. The recent sales—many at prices between $68 and $70—suggest that insiders are taking profits as the company’s valuation has surged year‑to‑date (+77 %). The fresh purchase indicates confidence that the stock’s upside potential remains, especially as PTC continues to advance its pipeline of orally administered treatments for rare genetic disorders and oncology indications. For investors, the 10b5‑1 plan mitigates concerns about self‑serving trades, as the plan was set up in September 2025 and the trades are executed at predetermined prices and dates.

Profile of Mark Boulding

Boulding’s insider history reveals a disciplined, rule‑based approach. Since early 2025, he has sold a total of roughly 25,000 shares at market‑close prices ranging from $62.89 to $70.13, often in batches of several hundred to a few thousand. His buying activity is more sporadic but consistently executed under a 10b5‑1 framework, with the most recent acquisition in January 2023. The pattern of periodic selling, followed by a new purchase, is typical for executives who want to balance liquidity needs with long‑term commitment to the company.

Implications for PTC’s Future

With a market cap of $5.7 billion and a trailing P/E of 8.9, PTC remains attractively valued relative to its peers in the biotechnology sector. The insider activity suggests that senior leadership is not overly concerned about short‑term volatility but is looking to fund the company’s aggressive R&D pipeline. If the company continues to secure regulatory approvals and broaden its product portfolio, the 10b5‑1 purchases may foreshadow further upside. For shareholders, the current transaction is a positive signal that executives are willing to invest in their own shares, reinforcing confidence in PTC’s long‑term trajectory.